What is the current price of Corbus Pharmaceuticals'stock?
Since then, CRBP stock has decreased by 87.7% and is now trading at $0.5079. View which stocks have been most impacted by COVID-19. When is Corbus Pharmaceuticals' next earnings date? Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
What is the upside for Corbus pharmaceuticals (CPRP)?
6 Wall Street analysts have issued 12 month target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $3.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $2.88 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price.
When is Corbus pharmaceuticals'next quarterly earnings announcement?
Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022. View our earnings forecast for Corbus Pharmaceuticals. How were Corbus Pharmaceuticals' earnings last quarter?
Should you hold Corbus pharmaceuticals (CRBP) stock?
The consensus among Wall Street research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
Is corbus Pharmaceuticals a good stock to buy?
Out of 3 analysts, 1 (33.33%) are recommending CRBP as a Strong Buy, 0 (0%) are recommending CRBP as a Buy, 2 (66.67%) are recommending CRBP as a Hold, 0 (0%) are recommending CRBP as a Sell, and 0 (0%) are recommending CRBP as a Strong Sell. What is CRBP's earnings growth forecast for 2022-2024?
What is going on with corbus pharmaceuticals?
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates. Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022.
Why did corbus Pharmaceuticals stock drop?
Shares of Corbus Pharmaceuticals dropped Thursday on the news that its drug lenabasum has failed to effectively treat dermatomyositis in a late-stage trial. It's the third late-stage trial failure in a year for the same drug.
Will CRBP go up?
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) The 1 analysts offering 12-month price forecasts for Corbus Pharmaceuticals Holdings Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +934.48% increase from the last price of 0.29.
Will corbus pharmaceuticals go out of business?
Based on the latest financial disclosure, Corbus Pharma has a Probability Of Bankruptcy of 89%. This is 105.59% higher than that of the Healthcare sector and 62.29% higher than that of the Biotechnology industry.
Where is corbus Pharmaceuticals located?
Norwood, MassachusettsCorbus is based in Norwood, Massachusetts.
What is Lenabasum?
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2). It resolves inflammation and limits fibrosis.
Is Corbus Pharmaceuticals Holdings stock a Buy, Sell or Hold?
Corbus Pharmaceuticals Holdings stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 0 hold rat...
What was the 52-week low for Corbus Pharmaceuticals Holdings stock?
The low in the last 52 weeks of Corbus Pharmaceuticals Holdings stock was 0.21. According to the current price, Corbus Pharmaceuticals Holdings is...
What was the 52-week high for Corbus Pharmaceuticals Holdings stock?
The high in the last 52 weeks of Corbus Pharmaceuticals Holdings stock was 2.28. According to the current price, Corbus Pharmaceuticals Holdings is...
What are analysts forecasts for Corbus Pharmaceuticals Holdings stock?
The 3 analysts offering price forecasts for Corbus Pharmaceuticals Holdings have a median target of 10.33, with a high estimate of 22.00 and a low...
When did Corbus Pharmaceuticals release its earnings?
How much does Corbus Pharmaceuticals make?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01.
News & Analysis: Corbus Pharmaceuticals Holdings
How much money does Corbus Pharmaceuticals make? Corbus Pharmaceuticals has a market capitalization of $206.30 million and generates $3.94 million in revenue each year. The biopharmaceutical company earns $-111,270,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.
Key Data Points
The Fool has written over 100 articles on Corbus Pharmaceuticals Holdings.
Environmental, Social, and Governance Rating
Primary metrics and data points about Corbus Pharmaceuticals Holdings.
How to calculate restricted stock?
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
How long are futures trading delayed?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.